Best Epithalon source is a question most pages answer backwards. They pick a winner, then describe the criteria that happen to produce it. The weighting below is written first, applied to six categories of seller, and the row that comes top gets marked down in public for the two places it falls short.
Key takeaways
- Testing scope carries 30 of the 100 marks, because FDA's stated concern with this substance is immunogenicity from aggregation and peptide-related impurities, and that is measured rather than asserted.
- The compounding pharmacy category is not scored low, it is disqualified. Epitalon was nominated, placed in category 2 under the interim policies, then withdrawn, and now sits on no current category list.
- The winning category takes 94 of 100 and loses marks in two places, one of them the price per measured milligram rather than the label milligram.
- The published certificate reports 9.64 mg in a vial labelled 10 mg. Inside the stated tolerance, under the printed weight, and the reason the real figure is $2.59 per milligram rather than $2.50.
- Winning this scorecard means a supplier documents what it sells. It is not evidence that Epithalon does anything, and a lifter should be clear which of the two they are buying.
The category that tops the ranking is represented by one real listing, and it is here rather than at the end so you can check the marks against it as you read.
The vendor we point lifters to
Epithalon from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The certificate for batch 15-05260628 assays this vial at 9.64 mg against a 10 mg label, inside the stated 10 percent tolerance, which puts the real figure at $2.59/mg on that batch. It carries purity, identity, endotoxin, sterility and heavy metals. Buying 3, 5 or 10 takes 3%, 5% or 10% off list.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 23, 2026.
The weighting, fixed before anything is ranked
| Criterion | Weight | Why it is weighted that way |
|---|---|---|
| Testing scope on the shipped lot | 30 | It is the only criterion that measures the risk FDA has actually named |
| Batch traceability | 20 | A certificate with no lot on it describes a company, not your vial |
| Honesty of the reported figures | 15 | Whether measured numbers are published even when they are unflattering |
| Domestic supply and dispatch | 15 | Removes customs entirely and shortens the transit nobody can audit |
| Price per measured milligram | 10 | Real, but it is the criterion most readers already over-weight |
| Conduct and compliance | 10 | Whether the seller stays off medical claims and dosing |
Two things in that table are deliberate. Price gets a tenth, not a half, because paying less for material you cannot describe is not a saving. And honesty of reporting is separated from testing scope, because publishing a number and publishing a flattering number are different behaviours.
Best Epithalon source: six categories against that weighting
| Category | Testing 30 | Trace 20 | Honesty 15 | Domestic 15 | Price 10 | Conduct 10 | Total |
|---|---|---|---|---|---|---|---|
| Domestic research supplier with lot certificates | 26 | 20 | 15 | 15 | 8 | 10 | 94 |
| Domestic research supplier, brand-level testing only | 8 | 4 | 3 | 15 | 7 | 7 | 44 |
| Longevity or anti-ageing clinic | 6 | 2 | 2 | 15 | 1 | 8 | 34 |
| Overseas bulk seller or group buy | 3 | 2 | 2 | 0 | 10 | 4 | 21 |
| Oral capsule storefront | 2 | 1 | 0 | 10 | 0 | 5 | 18 |
| Compounding pharmacy | Disqualified | Not scored |
The gap between the first and second rows is fifty marks, and both rows are domestic businesses selling the same compound at similar prices. That gap is the entire argument of this article: the category label tells you almost nothing, and the documents tell you almost everything.
Why testing scope takes almost a third of the marks
FDA's written position on this substance is narrow and specific, and it is what the heaviest weight is calibrated against. Compounded drugs containing epitalon, the agency states on its safety risks page, content current as of 04/22/2026, "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities", adding that it "has not identified safety-related information regarding epitalon for the proposed route of administration".
Read that as a manufacturing statement. Aggregation and peptide-related impurities are consequences of synthesis, purification, drying, filling, transport and storage. They are not properties of the molecule that a purity headline would expose, because purity asks what fraction of the powder is the target compound and says nothing about what travelled with it. Bacterial endotoxin is the measurable end of the same problem and persists long after the organisms that produced it are gone.
So testing scope is not a proxy for quality. It is the closest available measurement of the specific risk the regulator has named, which is why it outweighs price three to one here. The same weighting logic, on a compound where the documentation gap between two lots was the story, is in the best Selank source.
The category that cannot be scored at all
The compounding pharmacy row is disqualified rather than marked down, and the reason is worth stating precisely because plenty of pages get it wrong in one direction or the other.
Epitalon was nominated as a bulk drug substance for use in compounding. It was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was later withdrawn by the nominator. It appears on FDA's safety risks page under "Bulk drug substances nominated but withdrawn", a table the agency describes as covering substances previously in category 2 that the nominators pulled, and it is absent from the 503A bulk substances page, content current as of 05/14/2026, in every category.
So "Epitalon was in category 2" is stale, "Epitalon is category 2" is wrong, and "Epitalon is on no current category list" is accurate. There is no FDA approval for it either. A pharmacy has nothing to compound against and a prescriber has nothing to write, so the row is empty rather than expensive.
The clinic row, scored honestly
Longevity and anti-ageing clinics genuinely market this compound, which separates it from most peptides covered here, and the 34 marks it takes are not an accusation.
It scores fifteen on domestic supply because the material is in the country and nothing crosses a border, and eight on conduct because a licensed practitioner is operating under professional obligations a storefront does not have. It scores badly everywhere the documents live. A clinic is under no duty to disclose the manufacturer, the lot, or what the certificate for that lot covered, and in practice most do not, so testing scope and traceability collapse to whatever you can extract by asking.
Price takes one mark out of ten, which is arithmetic rather than a judgement. You are paying for consultation, administration and premises alongside the compound, and that is a legitimate thing to buy if supervision is what you want. It just makes the per-milligram comparison meaningless.
The top row, and the two places it loses marks
Here is the working behind 94, because a score with no arithmetic under it is an assertion.
The certificate behind the listing above covers batch 15-05260628, analysed by Kovera Labs, report KVR-2026-A36FF4, certified 05/23/2026. It reports purity at 99.312% against a greater-than-98% specification, confirmed identity, an endotoxin screen against a 0.5 EU/mL acceptance limit reported as a pass, a microbial sterility screen returning no growth, heavy metals including arsenic, cadmium and mercury screened, and a measured net content. That covers every axis the testing criterion asks about, so it takes 26 of 30 rather than the full 30 for one reason: only a single certificate is published for this compound, where the two other Russian peptides on this site carry two documents apiece from two laboratories. Testing scope belongs to a batch, so a second independent look at the same lot is worth something and is not there.
Traceability takes the full 20, since the lot is named on the report and printed on the vial. Honesty takes the full 15, and this is the interesting one. The reported net content is 9.64 mg against a 10 mg label, with a specification of 10 mg plus or minus 10 percent. That is inside tolerance and under the printed weight, and publishing it was the commercially inconvenient option. The cheap move is to copy the label figure into the results column. A vendor that weighs the fill and prints a number working against its own packaging is running certificates as records rather than as marketing, and it is the opposite case to the neighbouring lot that assayed over its label, covered in the best NAD+ source.
Price takes 8 of 10, and the deduction comes straight out of that same number. At $25.00 with the code the label arithmetic gives $2.50 per milligram. Against the 9.64 mg actually measured it is $2.59. Both figures are true, the second one is what you paid, and this site publishes both every time. Domestic dispatch and conduct take their full marks.
What first place still does not buy
Ninety-four out of a hundred describes a supply chain, and readers of this site are mostly lifters in their forties, fifties and beyond who deserve the distinction stated plainly.
Epithalon is a synthetic tetrapeptide, four residues, Ala-Glu-Asp-Gly, listed by PubChem as Epitalon under CID 219042 with the formula C14H22N4O9 and a molecular weight of 390.35. Its reputation rests on telomere, telomerase and longevity claims that originate largely with Vladimir Khavinson's group in Russia, largely in Russian-language publications, and have not been replicated to Western standards. The PubMed record is concentrated in that lineage, and ClinicalTrials.gov lists no registered study with the compound as an intervention.
None of that is a training claim, and the vendors are not making one. You would be buying an anti-ageing proposition with thin verification, delivered in an unusually well documented vial, and those two things should not be allowed to blur into each other. If what has actually changed is how much hard work you can absorb and recover from, the biology behind that is far better mapped, and we cover it in myostatin and sarcopenia.
Frequently asked questions
What makes one Epithalon vendor better than another?
The report for the lot they are shipping. Two domestic sellers at similar prices can differ by fifty marks on this scorecard purely on whether the certificate names your batch and covers identity, purity against a stated specification, endotoxin, sterility and a measured net content.
Is the cheapest source ever the best source for Epitalon?
Price carries ten of a hundred marks here, so it can move a close ranking and cannot win one. Overseas bulk takes full marks on price and still finishes near the bottom, because it forfeits traceability, domestic dispatch and any recourse when a parcel is stopped.
Why does the top vendor lose marks at all?
For two things. Only one certificate is published for this compound, where the neighbouring Russian peptides each carry two, so a second independent look at the lot is missing. And the measured fill of 9.64 mg makes the true unit price $2.59 per milligram rather than the $2.50 the label implies.
Can a clinic be the best place to buy Epithalon?
It can be the right choice if what you want is supervision, and it still scores poorly on this weighting because sourcing is undisclosed. Ask which lot you are being given and what its certificate covered. A clinic that answers has earned its markup, and one that deflects has answered a different question.
Does a top score mean Epithalon is worth buying?
No. The scorecard measures how well a seller documents what is in the vial. It says nothing about effect, and the telomere and longevity claims behind this compound come from a narrow, largely Russian-language research base with no registered trials listing it as an intervention.
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA
- Bulk Drug Substances Used in Compounding Under Section 503A, FDA
- Epitalon, PubChem CID 219042
- Certificate of analysis, Epithalon batch 15-05260628, Kovera Labs
- Published research on epitalon, PubMed
- Registered studies of Epitalon, ClinicalTrials.gov
This article is for educational purposes only and is not medical advice. Epithalon holds no FDA approval for any indication, has no US prescription route, and material sold by research suppliers is labelled for laboratory use only and not for human consumption. Claims about telomeres, telomerase and lifespan associated with this compound come largely from a single research lineage and have not been replicated to Western regulatory standards. Speak with a qualified healthcare professional before making any decision involving peptides, injections or unapproved compounds.